drugset / Trial / NCT05203562

Letrozole as a Prophylaxis From GTN for Complete Mole Patients

NCT05203562

Phase 2/3 Unknown 200 enrolled Zagazig University
RandomizedParallel-groupSingle-blindPrevention

Summary

Prophylactic use of aromatase inhibitor is effective in decreasing the incidence of Gestational Trophoblastic Neoplasia (GTN) in patients with complete hydatidiform mole (CHM)

Timeline

Start
2020-06-01
Primary completion
2022-12-01
Completion
2023-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 5 mg